Ralph Niven, CHIEF SCIENTIFIC OFFICER at Aerovate Therapeutics, Inc. (AVTE), sold 2,250 shares at $19.11 ($41K) on 2023-04-05, disclosed to the SEC on 2023-04-07.
Scheduled sale ($41k) by CHIEF SCIENTIFIC OFFICER under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $17.91 | 1,715 | $31K | 75.0% |
| 2 | $19.11 | 535 | $10K | 25.0% |
| Total | $18.20 avg | 2,250 | $41K | 100% |
| Filing → |
| AVTE | SELL | 2023-12-07 | $75K | — | Filing → |
| AVTE | SELL | 2023-11-27 | $207K | — | Filing → |
| AVTE | SELL | 2023-07-07 | $39K | — | Filing → |